Literature DB >> 22345441

A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility.

Henry Grisé1, Stephen Frausto, Timothy Logan, Hengli Tang.   

Abstract

Cyclophilin A (CyPA) and its peptidyl-prolyl isomerase (PPIase) activity play an essential role in hepatitis C virus (HCV) replication, and mounting evidence indicates that nonstructural protein 5A (NS5A) is the major target of CyPA. However, neither a consensus CyPA-binding motif nor specific proline substrates that regulate CyPA dependence and sensitivity to cyclophilin inhibitors (CPIs) have been defined to date. We systematically characterized all proline residues in NS5A domain II, low-complexity sequence II (LCS-II), and domain III with both biochemical binding and functional replication assays. A tandem cyclophilin-binding site spanning domain II and LCS-II was identified. The first site contains a consensus sequence motif of AØPXW (where Ø is a hydrophobic residue) that is highly conserved in the majority of the genotypes of HCV (six of seven; the remaining genotype has VØPXW). The second tandem site contains a similar motif, and the ØP sequence is again conserved in six of the seven genotypes. Consistent with the similarity of their sequences, peptides representing the two binding motifs competed for CyPA binding in a spot-binding assay and induced similar chemical shifts when bound to the active site of CyPA. The two prolines (P310 and P341 of Japanese fulminant hepatitis 1 [JFH-1]) contained in these motifs, as well as a conserved tryptophan in the spacer region, were required for CyPA binding, HCV replication, and CPI resistance. Together, these data provide a high-resolution mapping of proline residues important for CyPA binding and identify critical amino acids modulating HCV susceptibility to the clinical CPI Alisporivir.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22345441      PMCID: PMC3347344          DOI: 10.1128/JVI.06641-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon.

Authors:  Sue Ma; Joanna E Boerner; ChoiLai TiongYip; Beat Weidmann; Neil S Ryder; Michael P Cooreman; Kai Lin
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid.

Authors:  T R Gamble; F F Vajdos; S Yoo; D K Worthylake; M Houseweart; W I Sundquist; C P Hill
Journal:  Cell       Date:  1996-12-27       Impact factor: 41.582

3.  The NMR structure of cyclosporin A bound to cyclophilin in aqueous solution.

Authors:  C Weber; G Wider; B von Freyberg; R Traber; W Braun; H Widmer; K Wüthrich
Journal:  Biochemistry       Date:  1991-07-02       Impact factor: 3.162

4.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

Authors:  J J Siekierka; S H Hung; M Poe; C S Lin; N H Sigal
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

5.  DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.

Authors:  Lotte Coelmont; Xavier Hanoulle; Udayan Chatterji; Carola Berger; Joke Snoeck; Michael Bobardt; Precious Lim; Inge Vliegen; Jan Paeshuyse; Grégoire Vuagniaux; Anne-Mieke Vandamme; Ralf Bartenschlager; Philippe Gallay; Guy Lippens; Johan Neyts
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

6.  Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition.

Authors:  L D Zydowsky; F A Etzkorn; H Y Chang; S B Ferguson; L A Stolz; S I Ho; C T Walsh
Journal:  Protein Sci       Date:  1992-09       Impact factor: 6.725

7.  Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins.

Authors:  G Fischer; B Wittmann-Liebold; K Lang; T Kiefhaber; F X Schmid
Journal:  Nature       Date:  1989-02-02       Impact factor: 49.962

8.  Peptidyl-prolyl isomerase Pin1 is a cellular factor required for hepatitis C virus propagation.

Authors:  Yun-Sook Lim; Huong T L Tran; Soo-Je Park; Seung-Ae Yim; Soon B Hwang
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

9.  Cyclophilin inhibitors as a novel HCV therapy.

Authors:  Hengli Tang
Journal:  Viruses       Date:  2010-08-05       Impact factor: 5.818

10.  The isomerase active site of cyclophilin A is critical for hepatitis C virus replication.

Authors:  Udayan Chatterji; Michael Bobardt; Suganya Selvarajah; Feng Yang; Hengli Tang; Noayo Sakamoto; Gregoire Vuagniaux; Tanya Parkinson; Philippe Gallay
Journal:  J Biol Chem       Date:  2009-04-20       Impact factor: 5.157

View more
  26 in total

Review 1.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

2.  Intrinsic disorder mediates hepatitis C virus core-host cell protein interactions.

Authors:  Patrick T Dolan; Andrew P Roth; Bin Xue; Ren Sun; A Keith Dunker; Vladimir N Uversky; Douglas J LaCount
Journal:  Protein Sci       Date:  2014-12-31       Impact factor: 6.725

Review 3.  Hepatitis C virus-host interactions, replication, and viral assembly.

Authors:  Ana Shulla; Glenn Randall
Journal:  Curr Opin Virol       Date:  2012-10-18       Impact factor: 7.090

4.  Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors.

Authors:  Anita Nag; Jason M Robotham; Hengli Tang
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

5.  Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.

Authors:  Jose A Garcia-Rivera; Michael Bobardt; Udayan Chatterji; Sam Hopkins; Matthew A Gregory; Barrie Wilkinson; Kai Lin; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

6.  Cyclophilin A allows the allosteric regulation of a structural motif in the disordered domain 2 of NS5A and thereby fine-tunes HCV RNA replication.

Authors:  Marie Dujardin; Vanesa Madan; Neha S Gandhi; François-Xavier Cantrelle; Hélène Launay; Isabelle Huvent; Ralf Bartenschlager; Guy Lippens; Xavier Hanoulle
Journal:  J Biol Chem       Date:  2019-07-17       Impact factor: 5.157

7.  The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.

Authors:  Udayan Chatterji; Jose A Garcia-Rivera; James Baugh; Katarzyna Gawlik; Kelly A Wong; Weidong Zhong; Clifford A Brass; Nikolai V Naoumov; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

8.  Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility.

Authors:  Israr-Ul H Ansari; Todd Allen; Andrew Berical; Peter G Stock; Burc Barin; Rob Striker
Journal:  Virology       Date:  2013-01-02       Impact factor: 3.616

9.  A Proline-Tryptophan Turn in the Intrinsically Disordered Domain 2 of NS5A Protein Is Essential for Hepatitis C Virus RNA Replication.

Authors:  Marie Dujardin; Vanesa Madan; Roland Montserret; Puneet Ahuja; Isabelle Huvent; Helene Launay; Arnaud Leroy; Ralf Bartenschlager; François Penin; Guy Lippens; Xavier Hanoulle
Journal:  J Biol Chem       Date:  2015-06-17       Impact factor: 5.157

10.  Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A.

Authors:  Claire Rosnoblet; Bernd Fritzinger; Dominique Legrand; Hélène Launay; Jean-Michel Wieruszeski; Guy Lippens; Xavier Hanoulle
Journal:  J Biol Chem       Date:  2012-11-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.